Chemotherapy-induced nausea and vomiting - Standards in 2012

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy Induced Nausea and Vomiting 100%
• Receptor Antagonist 55%
• Antiemetic Agent 44%
• Dexamethasone 22%
• Substance P 22%
• Chemotherapy 11%
• Antipsychotic 11%
• Dopamine Receptor Blocking Agent 11%
• Serotonin 3 Antagonist 11%
• Malignant Neoplasm 11%
• Adverse Event 11%
• Nausea 11%
• Anticarcinogen 11%
• Nausea and Vomiting 11%
• Cyclophosphamide 11%
• Neurokinin 1 Receptor Antagonist 11%
• Anthracycline 11%
• Aprepitant 11%
• Palonosetron 11%
• Fosaprepitant 11%
• Cannabinoid 11%

Keyphrases

• Chemotherapy-induced Nausea 100%
• Receptor Antagonist 27%
• 5-HT3 16%
• Clinical Practice Guidelines 16%
• Nausea 11%
• New Drugs 11%
• Vomiting 11%
• Antiemetic Prophylaxis 11%
• Neurokinin-1 11%
• Antiemetic Agents 11%
• Delayed Chemotherapy 11%
• Benzodiazepines 5%
• Cannabinoids 5%
• Cancer Patients 5%
• In Cancer 5%
• Adverse Effects 5%
• Chemotherapy 5%
• Current Treatment 5%
• Clinical Problems 5%
• Targeted Therapy 5%
• Cyclophosphamide 5%
• Corticosteroids 5%
• Equivalency 5%
• Non-adherence 5%
• Anthracyclines 5%
• Singles' Day 5%
• Antineoplastic Drugs 5%
• 5-HT3 Receptor Antagonist 5%
• Triple Therapy 5%
• Neurokinin-1 Receptor Antagonist 5%
• Oral Therapy 5%
• Palonosetron 5%
• Aprepitant 5%
• Delayed Phase 5%
• Fosaprepitant 5%
• Antiemetic Treatment 5%
• Dopamine Receptor Antagonist 5%
• MASCC 5%
• Number of Patients 5%
• Highly Emetogenic 5%